NL-OMON31737撤回2 期
A Phase I/II study to determine the safety and efficacy of a combination of anti-CD3 & anti-CD7 ricin A immunotoxins for treating steroid-resistant acute graft-versus-host disease. - IT-combination for aGVHD
Henogen S.A.0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients suffering from severe acute GVHD (Grade II-IV) that is progressing after 3 days, or non-improving after 5 days, of prednisolone at 2 mg/kg a day.
排除标准
- •Patients receiving concomitant investigational therapeutics for acute GVHD, including agents used for GVHD prophylaxis, at the time of enrollment.
研究者
相似试验
已完成
2 期
A Phase I/II study to determine the safety and efficacy of a combination of anti-CD3 & anti-CD7 ricin A immunotoxins (T-Guard) for treating steroid-resistant acute graft-versus-host disease.GVHDNL-OMON44132Xenikos BV10
招募中
1 期
Injection of Bromelain and Acetylcysteine in combination into recurrent mucinous tumour or pseudomyxoma peritonei: a phase I/II studyrecurrent pseudomyxoma peritoneiperitoneal diseaselow grade appendix tumourCancer - Other cancer typespseudomyxoma peritoneiACTRN12617001612303Professor David Morris60
招募中
1 期
A Phase I/II study to assess the safety and efficacy of full-spectrum medicinal cannabis plant extract 0.08% THC (NTI164) in the treatment of Rett syndrome (RTT)Rett SyndromeNeurological - Neurodegenerative diseasesACTRN12623000563662Fenix Innovation Group14
进行中（未招募）
1 期
Phase I/II Study to Evaluate the Safety and Efficacy of JB-101(Induced T Cell With Suppressing Functions), to Induce Operational Tolerance in Living Donor Liver Transplantation.JPRN-jRCT2073200067chida Koichiro10
进行中（未招募）
1 期
Phase I/II Study of MK-3475 in Combination with Trametinib and Dabrafenibadvanced or metastatic melanoma - all parts of the trialadvanced (unresectable and/or metastatic) solid tumours - Parts 4 and 5MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2015-000681-55-DKMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.190